ライフサイエンスコーパス: thromboemboli

1 thologic findings (aspiration, pneumonia, or thromboemboli).

2 e interval, 1.4-21.1]); male sex; and venous thromboemboli.

3 s of acute deep venous thrombi and pulmonary thromboemboli.

4 als after antibody infusion to visualize the thromboemboli.

5 ulmonary hypertension resulting from chronic thromboemboli.

6 ntrast has been linked to the development of thromboemboli.

7 exposure, with or without arterial or venous thromboemboli.

8 is the source of the vast majority of these thromboemboli.

9 phenomena, atheroemboli and, more commonly, thromboemboli.

10 ue to collagen/epinephrine-induced pulmonary thromboemboli.

11 source-to-destination transport patterns of thromboemboli as a function of: LVAD outflow graft anast

12 patients with recurrent or life-threatening thromboemboli, but decisions about this are best made on

13 with lung disease, sleep apnea, and chronic thromboemboli can develop pulmonary hypertension, curren

14 omboembolism-induced mortality and decreased thromboemboli dissolution in vivo.

15 We also found that cardiogenic thromboemboli do not have an altered hemisphere distribu

16 19-positive autopsy cases to intramyocardial thromboemboli from COVID-19 cases as well as to aspirate

17 ifferent in composition from intramyocardial thromboemboli from COVID-19-negative subjects and from c

18 immunostaining compared with intramyocardial thromboemboli from COVID-19-negative subjects and with a

19 Across all cases considered, thromboemboli from left and right carotid sources showed

20 s with sleep apnea, lung disease, or chronic thromboemboli identifies a progressive gradient for dyna

21 ture could promote the transition from acute thromboemboli into chronic obstructive vascular scars.

22 echnique reliably identified even peripheral thromboemboli of relatively small size, which are diffic

23 agulable workup in the absence of additional thromboemboli or laboratory abnormalities or family hist

24 ate proximal pulmonary arterial occlusion by thromboemboli or, rarely, other processes such as tumors

25 ng hemangiomatosis-like changes (P = 0.043), thromboemboli (P = 0.0038), pulmonary infarcts (P = 0.04

26 ected RBC/tPA rapidly lysed nascent cerebral thromboemboli, providing rapid, durable reperfusion and

27 to study source-to-destination transport of thromboemboli released from left/right carotid disease s

28 Previous attempts to diagnose thromboemboli using radiolabeled antibodies and nuclear

29 unized antifibrin Fab' fragments to diagnose thromboemboli using single photon emission computed tomo

30 Thromboemboli were also present in other organs, includi

31 No treatment related infarcts or thromboemboli were observed in the downstream organs.

32 prominent fibrin deposits and intravascular thromboemboli were observed in tissues of some animals t

33 Thromboemboli were venous (12 patients, 7 with pulmonary

34 to study methods that rapidly remove venous thromboemboli while minimizing the risk.

35 Mechanical removal of thromboemboli with stent retrievers can quickly and effe